Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line

Zika virus (ZIKV) is a Flavivirus associated with several neurological complications. Currently, there are no vaccines or cures available and an efficient antiviral treatment is urgently needed to combat ZIKV infection. Herein, we targeted ZIKV NS2B-NS3 serine protease with short peptides to inhibit...

Full description

Bibliographic Details
Main Authors: Abdulrahman, Ammar Yasir, Khazali, Ahmad Suhail, Teoh, Teow Chong, Rothan, Hussin A., Yusof, Rohana
Format: Article
Published: Springer Verlag 2019
Subjects:
_version_ 1796961987027009536
author Abdulrahman, Ammar Yasir
Khazali, Ahmad Suhail
Teoh, Teow Chong
Rothan, Hussin A.
Yusof, Rohana
author_facet Abdulrahman, Ammar Yasir
Khazali, Ahmad Suhail
Teoh, Teow Chong
Rothan, Hussin A.
Yusof, Rohana
author_sort Abdulrahman, Ammar Yasir
collection UM
description Zika virus (ZIKV) is a Flavivirus associated with several neurological complications. Currently, there are no vaccines or cures available and an efficient antiviral treatment is urgently needed to combat ZIKV infection. Herein, we targeted ZIKV NS2B-NS3 serine protease with short peptides to inhibit ZIKV replication in human hepatic cell line (WRL-68). The short peptide inhibitors were designed using Hyperchem 8.0.10 software. Docking energy and binding configuration were calculated using HADDOCK webserver. ZIKV NS2B-NS3 protease was produced as a recombinant single peptide in Escherichia coli and the protease activity was examined by measuring the cleavage of a fluorescent substrate in the presence of the peptides or aprotinin as a standard protease inhibitor. Computational analysis revealed that the short peptides, AYA2 and AYA9, exhibited lower docking energy to ZIKV protease than aprotinin. Both peptides also possessed lower half maximal inhibitory concentration (IC50), 30.9 and 22.1 µM respectively, against ZIKV protease activity when compared to aprotinin (35.4 µM). Interestingly, AYA2 and AYA9 exhibited minimal cytotoxic effects in WRL-68 cells and showed considerable inhibition against ZIKV replication in vitro at half maximal effective concentration (EC50) of 40.73 ± 2.3 µM and 34.65 ± 1.8 µM respectively. Fusion of these two peptides to MAP30 peptide substantially reduced the IC50 of ZIKV protease inhibition to 1.1 µM and inhibited ZIKV replication at EC50 of 0.5157 ± 0.03 µM. In sum, we reported novel peptides that effectively inhibited ZIKV replication in vitro. This study represents a cost-effective strategy of developing peptide inhibitors by shortening the peptides and producing them in recombinant form. © 2019, Springer Nature B.V.
first_indexed 2024-03-06T06:02:19Z
format Article
id um.eprints-24276
institution Universiti Malaya
last_indexed 2024-03-06T06:02:19Z
publishDate 2019
publisher Springer Verlag
record_format dspace
spelling um.eprints-242762020-05-08T04:36:45Z http://eprints.um.edu.my/24276/ Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line Abdulrahman, Ammar Yasir Khazali, Ahmad Suhail Teoh, Teow Chong Rothan, Hussin A. Yusof, Rohana R Medicine Zika virus (ZIKV) is a Flavivirus associated with several neurological complications. Currently, there are no vaccines or cures available and an efficient antiviral treatment is urgently needed to combat ZIKV infection. Herein, we targeted ZIKV NS2B-NS3 serine protease with short peptides to inhibit ZIKV replication in human hepatic cell line (WRL-68). The short peptide inhibitors were designed using Hyperchem 8.0.10 software. Docking energy and binding configuration were calculated using HADDOCK webserver. ZIKV NS2B-NS3 protease was produced as a recombinant single peptide in Escherichia coli and the protease activity was examined by measuring the cleavage of a fluorescent substrate in the presence of the peptides or aprotinin as a standard protease inhibitor. Computational analysis revealed that the short peptides, AYA2 and AYA9, exhibited lower docking energy to ZIKV protease than aprotinin. Both peptides also possessed lower half maximal inhibitory concentration (IC50), 30.9 and 22.1 µM respectively, against ZIKV protease activity when compared to aprotinin (35.4 µM). Interestingly, AYA2 and AYA9 exhibited minimal cytotoxic effects in WRL-68 cells and showed considerable inhibition against ZIKV replication in vitro at half maximal effective concentration (EC50) of 40.73 ± 2.3 µM and 34.65 ± 1.8 µM respectively. Fusion of these two peptides to MAP30 peptide substantially reduced the IC50 of ZIKV protease inhibition to 1.1 µM and inhibited ZIKV replication at EC50 of 0.5157 ± 0.03 µM. In sum, we reported novel peptides that effectively inhibited ZIKV replication in vitro. This study represents a cost-effective strategy of developing peptide inhibitors by shortening the peptides and producing them in recombinant form. © 2019, Springer Nature B.V. Springer Verlag 2019 Article PeerReviewed Abdulrahman, Ammar Yasir and Khazali, Ahmad Suhail and Teoh, Teow Chong and Rothan, Hussin A. and Yusof, Rohana (2019) Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line. International Journal of Peptide Research and Therapeutics, 25 (4). pp. 1659-1668. ISSN 1573-3149, DOI https://doi.org/10.1007/s10989-019-09808-4 <https://doi.org/10.1007/s10989-019-09808-4>. https://doi.org/10.1007/s10989-019-09808-4 doi:10.1007/s10989-019-09808-4
spellingShingle R Medicine
Abdulrahman, Ammar Yasir
Khazali, Ahmad Suhail
Teoh, Teow Chong
Rothan, Hussin A.
Yusof, Rohana
Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line
title Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line
title_full Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line
title_fullStr Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line
title_full_unstemmed Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line
title_short Novel Peptides Inhibit Zika NS2B-NS3 Serine Protease and Virus Replication in Human Hepatic Cell Line
title_sort novel peptides inhibit zika ns2b ns3 serine protease and virus replication in human hepatic cell line
topic R Medicine
work_keys_str_mv AT abdulrahmanammaryasir novelpeptidesinhibitzikans2bns3serineproteaseandvirusreplicationinhumanhepaticcellline
AT khazaliahmadsuhail novelpeptidesinhibitzikans2bns3serineproteaseandvirusreplicationinhumanhepaticcellline
AT teohteowchong novelpeptidesinhibitzikans2bns3serineproteaseandvirusreplicationinhumanhepaticcellline
AT rothanhussina novelpeptidesinhibitzikans2bns3serineproteaseandvirusreplicationinhumanhepaticcellline
AT yusofrohana novelpeptidesinhibitzikans2bns3serineproteaseandvirusreplicationinhumanhepaticcellline